

STATEMENT OF CONFIRMATIONS

Completion of Public Offer

HeraMED Limited ACN 626 295 314 (**Company**) confirms that the public offer (**Public Offer**) under the Company's prospectus dated 15 October 2018 as modified by a supplementary prospectus dated 23 November 2018 (**Prospectus**) has completed and the Company has issued 30,000,000 fully paid ordinary shares (**Shares**) under the Public Offer.

Completion of Additional Offers

The Company confirms that the offers of:

- 33,728,841 Shares and 3,671,159 options exercisable at \$0.00002 each or before 5 December 2021 (**Vendor Options**) to the vendors of Hera-MED Limited (Registration number P.C. 51-467654-3 (**HeraMED Israel**) (**Vendor Offer**);
- 17,200,000 Shares and 8,600,000 options exercisable at \$0.25 each on or before 5 December 2021 (**New Options**) on conversion of the convertible notes (as defined in the Prospectus) (**Noteholder Offer**);
- 7,500,000 New Options to the Executive Directors (or their nominees) (**Management Offer**); and
- 7,500,000 New Options to Twenty 1 Corporate (or its nominees) (**Broker Offer**),

(**Additional Offers**) under the Prospectus have completed and the Company has issued a total of 50,928,841 Shares, 3,671,159 Vendor Options and 23,600,000 New Options under the Additional Offers.

All Convertible Notes have now been fully converted.

Completion of additional issue of Shares

The Company confirms that 550,000 Shares have been issued to a nominee of the corporate advisers, and that a total of 6,600,000 Shares are held by the corporate advisers (or their nominees) pursuant to the corporate mandate.

Completion of Acquisition

The Company confirms the conditions precedent to the acquisition of 100% of HeraMED Israel (**Acquisition**) have been satisfied (not waived), and the Acquisition was completed on 5 December 2018. As stated above, the Company has issued 33,728,841 Shares and 3,671,159 Vendor Options pursuant to the Vendor Offer to the vendors of HeraMED Israel as part consideration for the Acquisition.

Approval for termination benefits

The Company confirms that it has obtained shareholder approval under sections 200B and 200E of the *Corporations Act 2001* (Cth) for the termination benefits referred to in section 7.7(f) of the Prospectus.